MARKET

SLN

SLN

Silence Therapeutics Plc
NASDAQ
13.58
-1.14
-7.74%
Pre Market: 14.22 +0.64 +4.71% 07:42 08/13 EDT
OPEN
14.75
PREV CLOSE
14.72
HIGH
15.24
LOW
13.55
VOLUME
315
TURNOVER
0
52 WEEK HIGH
17.58
52 WEEK LOW
4.190
MARKET CAP
641.61M
P/E (TTM)
-8.5479
1D
5D
1M
3M
1Y
5Y
1D
Silence Therapeutics Announces Major ADS Public Offering
TipRanks · 13h ago
Morgan Stanley maintains Overweight rating on Silence Therapeutics
Seeking Alpha · 1d ago
Silence Therapeutics Is Maintained at Overweight by Morgan Stanley
Dow Jones · 1d ago
Morgan Stanley Maintains Overweight on Silence Therapeutics, Raises Price Target to $32
Benzinga · 1d ago
Silence Therapeutics price target raised to $32 from $25 at Morgan Stanley
TipRanks · 1d ago
Silence Therapeutics (SLN) Receives a Buy from Morgan Stanley
TipRanks · 1d ago
Silence Therapeutics Announces Public Offering Worth $150 Mln In American Depositary Shares
NASDAQ · 2d ago
Biotech Stocks At 52-Week Highs - SLN +29% & ABCL +34% On Positive Trial Data, CPIX, CLDX, BDSX
NASDAQ · 2d ago
More
About SLN
Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The Company leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The Company focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca.

Webull offers Silence Therapeutics PLC - ADR stock information, including NASDAQ: SLN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SLN stock methods without spending real money on the virtual paper trading platform.